Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Generx: Phase I/II

CLTX said that preliminary results from its 67-patient placebo-controlled U.S. Phase I/II AGENT trial

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE